Abstract: Arsenic trioxide（ATO），a traditional Chinese medicine with a longstanding history，is renowned for its efficacy in the treatment of acute promyelocytic leukemia（APL）. Recently，more and more studies have demonstrated that ATO exhibits anti-tumor effects across a variety of malignancies，and it also showed some effects in the clinical treatment of pediatric tumors，which deserves further study. The lack of established guidelines and consensus regarding its clinical application in pediatric solid tumors has prompted the Specialty Committee of Pediatric Oncology of the Chinese Anti-Cancer Association and the Specialty Committee of Pediatric Oncology of Guangdong Anti-Cancer Association to organize domestic experts to make literature review and analysis and summary regarding the history of ATO，its anti-tumor mechanisms，its clinical application，and its pharmacokinetics. A full discussion was carried out concerning the indications，administration methods and the management of adverse reactions associated with ATO use in pediatric solid tumors，and reasonable suggestions were put forward based on evidence-based medical evidence and clinical experience，aiming to provide clinicians with evidence for the rational use of ATO in order to better improve the prognosis of pediatric patients with tumors and offer valuable references for pharmaceutical management departments.

Key words: arsenic trioxide, tumor, pediatric, clinical application, consensus

摘要： 三氧化二砷（ATO）是一种具有悠久应用历史的中国传统药物，因对急性早幼粒细胞白血病（APL）的卓越疗效而被熟知。近年越来越多的研究表明ATO在多种实体瘤中具有抗肿瘤作用，在儿童肿瘤的临床治疗中亦展现出一定效果，值得进一步探索；但因其在儿童实体肿瘤患者的临床应用缺乏相关的指引和共识，为此，中国抗癌协会小儿肿瘤专业委员会、广东省抗癌协会小儿肿瘤专业委员会组织国内相关专家对ATO的历史来源、抗肿瘤作用机制及临床应用、药代动力学进行文献复习及分析总结，针对ATO临床应用于儿童实体肿瘤的适应证、用药方法及不良反应处理等实际问题进行充分讨论，并基于循证医学证据及临床经验提出合理建议，旨在为临床医师提供合理用药依据，以期更好地改善儿童肿瘤患者的预后，同时为医药管理部门提供参考。

关键词: 三氧化二砷, 肿瘤, 儿童, 临床应用, 共识